Although Bcl-2 was shown to be related to decreased survival and malignant potential in urothelial transitional cell cancer (Bilim et al, 1996), oesophagus cancer (Hsia et al, 2001), prostate cancer (Bauer et al, 1996) and other cancers, we demonstrated here that Bcl-2 is an independent favourable prognostic factor in RCC patients. This evidence concerns the gene BCL2 and esophageal cancer.